You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Rhinology

The Pathophysiology of Type 2 Inflammation in CRSwNP

Learn how type 2 inflammation underlies the pathophysiology of CRSwNP

Download

Learning objectives

  • Learn about the key cytokines involved in type 2 inflammation underlying CRSwNP
  • Understand the effects of the interaction between type 2 inflammation and barrier dysfunction

Description

Use this educational tool to explore the pathophysiology of type 2 inflammation that underlies CRSwNP.

Tags
loss of smelltype 2 inflammationdisease control
MAT-GLB-2302767 v2.0 07/2023

Related resources

Partnering With Patients: Scores That Matter in CRSwNP
Rhinology
interactivity

Partnering With Patients: Scores That Matter in CRSwNP

The Pathophysiology of Type 2 Inflammation in CRSwNP
Rhinology
interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

Importance of Endotyping in CRSwNP
Rhinology
expert video

Importance of Endotyping in CRSwNP

Partnering With Patients for Clinical Decision-Making in CRSwNP
Rhinology
expert video

Partnering With Patients for Clinical Decision-Making in CRSwNP

Living With CRSwNP: A Type 2 Inflammatory Airway Disease
Rhinology
expert video

Living With CRSwNP: A Type 2 Inflammatory Airway Disease

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation
Rhinology
expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective
Rhinology
expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Rhinology
expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future
Rhinology
expert video

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Pulmonology
expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
Type 2 Inflammation
expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

What proportion of patients can achieve control in CRSwNP?
Type 2 Inflammation
expert video

What proportion of patients can achieve control in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Type 2 Inflammation
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Type 2 Inflammation
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Type 2 Inflammation
expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

When is the right time to consider a biologic in patients with CRSwNP?
Type 2 Inflammation
expert video

When is the right time to consider a biologic in patients with CRSwNP?

How often do you suggest to assess sense of smell?
Type 2 Inflammation
expert video

How often do you suggest to assess sense of smell?

How does a decrease in smell affect sleep disturbance? Is there any direct relation?
Rhinology
expert video

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Type 2 Inflammation
expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

ADVENT On Air | Loss of Smell in CRSwNP Patients
Rhinology
audio

ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Remission in CRSwNP
Rhinology
audio

ADVENT On Air | Remission in CRSwNP

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness
Rhinology
expert video

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease
Rhinology
expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness
Rhinology
expert video

Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

CEORL-HNS 2022 | Underlying Inflammation in Patients With Severe/Uncontrolled CRSwNP
Rhinology
expert video

CEORL-HNS 2022 | Underlying Inflammation in Patients With Severe/Uncontrolled CRSwNP

CRSwNP, Type 2 Inflammation, and Mechanisms of Action of Biologics
Rhinology
expert video

CRSwNP, Type 2 Inflammation, and Mechanisms of Action of Biologics

An Expert View: Defining CRSwNP as Severe and/or Uncontrolled, Discussing Treatment Options, and Partnering With Patients for Optimal Outcomes
Rhinology
expert video

An Expert View: Defining CRSwNP as Severe and/or Uncontrolled, Discussing Treatment Options, and Partnering With Patients for Optimal Outcomes

Efficacy, Comparative Efficacy, Effectiveness (RWE), and Safety of Treatment Options for Patients With Severe and/or Uncontrolled CRSwNP
Rhinology
expert video

Efficacy, Comparative Efficacy, Effectiveness (RWE), and Safety of Treatment Options for Patients With Severe and/or Uncontrolled CRSwNP

Chronic Type 2 Inflammation Causes Loss of Smell in CRSwNP
Rhinology
expert video

Chronic Type 2 Inflammation Causes Loss of Smell in CRSwNP

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
Rhinology
expert video

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP
Rhinology
expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

Expert Discussion: Partnering With Patients to Improve CRSwNP Outcomes
Rhinology
expert video

Expert Discussion: Partnering With Patients to Improve CRSwNP Outcomes

Clinical Management of CRSwNP: Maximizing Symptom Improvement
Rhinology
expert video

Clinical Management of CRSwNP: Maximizing Symptom Improvement

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
Rhinology
expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Optimizing Patient Outcomes in CRSwNP: Guidelines and Shared Decision-Making
Rhinology
expert video

ERS-ISIAN 2023 | Optimizing Patient Outcomes in CRSwNP: Guidelines and Shared Decision-Making

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
Rhinology
expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

Implementation of Guidelines into Daily Practice: Past, Present, and Future
Rhinology
expert video

Implementation of Guidelines into Daily Practice: Past, Present, and Future

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP
Rhinology
expert video

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP

Connecting Type 2 Inflammation to CRSwNP
Rhinology
expert video

Connecting Type 2 Inflammation to CRSwNP

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
Rhinology
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

CRSwNP: A Chronic Type 2 Inflammatory Disease
Rhinology
expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

Defining Mechanisms of Anosmia in CRSwNP
Rhinology
expert video

Defining Mechanisms of Anosmia in CRSwNP

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?
Rhinology
expert video

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region